Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING LLC

RNA Biomarker Assay Now Manufactured According to Strict ISO Regulatory Criteria

By Labmedica International staff writers
Posted on 19 Aug 2014
Image: RNAscope detects TP63 mRNA expression in human prostate tissue (Photo courtesy of Advanced Cell Diagnostics).
Image: RNAscope detects TP63 mRNA expression in human prostate tissue (Photo courtesy of Advanced Cell Diagnostics).
A line of diagnostic kits that measures RNA biomarkers with single-molecule sensitivity is now being manufactured under the stringent requirements of ISO 13485:2003 certification.

Advanced Cell Diagnostics, Inc. (Hayward, CA, USA), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, announced that the production facility for its line of RNAscope assays has received ISO 13485:2003 certification. ISO 13485:2003 certification, issued by the International Organization for Standardization (Geneva, Switzerland), the world's largest developer and publisher of international standards, regulates design, development, production, and commercialization for the implementation of quality management systems and various other technical and operational procedures.

Radioscope technology is the first automated multiplex RNA in situ hybridization platform capable of detecting and quantifying RNA biomarkers with single-molecule sensitivity. RNA expression levels are highly dynamic and integrate both genetic and epigenetic mechanisms of gene regulation. Thus, RNA expression reflects the state of a biological system. Measuring RNA biomarkers as RNA provides the most direct route for biomarker validation and assay development.

RNAscope employs a proven design strategy similar to fluorescence resonance energy transfer (FRET), in which two independent probes (double Z probes) must hybridize to the target sequence in tandem in order for signal amplification to occur. Because it is highly unlikely that two independent probes will hybridize to a nonspecific target right next to each other, this design concept ensures selective amplification of target-specific signals. For each target RNA species, 20 double Z target probe pairs are designed to specifically hybridize to the target molecule, but not to nontargeted molecules.

"Advanced Cell Diagnostics' vision is to make RNAscope the PCR equivalent for in situ nucleic acid detection and drive adoption of this technology in diagnostic tests," said Dr.Yuling Luo, president and CEO of Advanced Cell Diagnostics. "This ISO certification is the first step in our quality systems road map, which is designed to ensure that we supply products of the highest quality to our customers and provide a seamless path for our partners to translate scientific advances to patient benefits."

Related Links:

Advanced Cell Diagnostics, Inc.
International Organization for Standardization



KARL HECHT GMBH & CO KG
CELLAVISION AB
MEDLAB Asia

Channels

Genetic Tests

view channel
Image: For each chromosome, key SNPs are displayed above the chromosome and non-key SNPs below the chromosome, enabling users to determine the accuracy of haploblock calling. SNPs failed to be called are displayed as white points in the middle of the chromosome (Photo courtesy of Illumina).

Karyomapping Proposed as Alternative to Preimplantation Genetic Diagnosis for Evaluation of IVF Embryos

British researchers have suggested that karyomapping is a viable and cost-effective method for detecting a wide range of genetic diseases in IVF (in vitro fertilization) embryos. Preimplantation Genetic... Read more

Industry News

view channel
Image: Positive case of lung tissue stained for ALK with VENTANA ALK (D5F3) CDx Assay, a companion diagnostic immunohistochemical test in the final stages of the FDA premarket approval process (Photo courtesy of Ventana Medical Systems and PRNewsFoto).

Premarket Approval Sought for CDx Test to Benefit Lung Cancer Patients

Ventana Medical Systems, Inc. (Tucson, AZ, USA) has announced its US Food & Drug Administration (FDA) final stage submission for premarket approval (PMA) of its companion diagnostic (CDx) immunohistochemistry... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
18 Mar 2015 - 20 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.